FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Albert Kuivenhoven

Research Profile

Chemicals & Drugs

Physiology

Mutation

Disorders

Living Beings

Procedures

Co-author Network

Publications

TOP 3
Andrea E Bochem; Geesje M Dallinga-Thie; Menno Hoekstra; Adriaan G Holleboom; G Kees Hovingh; Jan Albert Kuivenhoven; Mohammad Mahdi Motazacker; Johannes A Romijn; Erik S G Stroes
High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C.
Menno Hoekstra; Suzanne J A Korporaal; Jan Albert Kuivenhoven; Theo J C Van Berkel; Ronald J van der Sluis; Andrea E Bochem; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Miranda van Eck
LCAT deficiency in mice is associated with a diminished adrenal glucocorticoid function.
A E Bochem; Jan Albert Kuivenhoven; E S G Stroes
The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Albert Kuivenhoven (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrea E Bochem; Geesje M Dallinga-Thie; Menno Hoekstra; Adriaan G Holleboom; G Kees Hovingh; Jan Albert Kuivenhoven; Mohammad Mahdi Motazacker; Johannes A Romijn; Erik S G Stroes
High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C.
Journal of lipid research 2013;54(6):1698-704.
2013: Menno Hoekstra; Suzanne J A Korporaal; Jan Albert Kuivenhoven; Theo J C Van Berkel; Ronald J van der Sluis; Andrea E Bochem; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Miranda van Eck
LCAT deficiency in mice is associated with a diminished adrenal glucocorticoid function.
Journal of lipid research 2013;54(2):358-64.
2013: A E Bochem; Jan Albert Kuivenhoven; E S G Stroes
The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease.
Current pharmaceutical design 2013;19(17):3143-9.
2012: Bas van den Bogaard; Raphaël Duivenvoorden; Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Erik S G Stroes; Bert-Jan H van den Born
Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness.
Atherosclerosis 2012;225(2):481-5.
2012: Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Angeliki Chroni; Georgios Daniil; Xiaoming Fu; Stanley L Hazen; Alinda W Schimmel; Erik S G Stroes; Sotirios Tsimikas; Joseph L Witztum; Renliang Zhang; Jan Albert Kuivenhoven
Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.
Arteriosclerosis, thrombosis, and vascular biology 2012;32(12):3066-75.
2012: Mohammad Mahdi Motazacker; Jorge Peter; James Pirruccello; Noam Zelcer; Stacey Gabriel; G Kees Hovingh; Roeland Huijgen; John J P Kastelein; Sekar Kathiresan; Jan Albert Kuivenhoven; Joep C Defesche; Ron Do; Sigrid W Fouchier
Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.
European heart journal 2012;33(11):1360-6.
2011: Raphaël Duivenvoorden; Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Aart J Nederveen; Alinda W Schimmel; Eric de Groot; Bas van den Bogaard; Erik S G Stroes
Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected].
Journal of the American College of Cardiology 2011;58(24):2481-7.
2011: Ratna Karuna; Jan Albert Kuivenhoven; Hugues Matile; Mohammad Mahdi Motazacker; Alaa Othman; Rebekka Park; Katharina M Rentsch; Lucia Rohrer; Markus Stoffel; Iryna Sutter; Adriaan G Holleboom; Thorsten Hornemann; Arnold von Eckardstein
Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism.
Atherosclerosis 2011;219(2):855-63.
2011: Adriaan G Holleboom; G Kees Hovingh; John J P Kastelein; Jan Albert Kuivenhoven; Frank Peelman; Jorge Peter; Alinda W Schimmel; Erik S Stroes; Joep C Defesche; Mohammad Mahdi Motazacker
High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations.
Human mutation 2011;32(11):1290-8.
2011: Andrew J Murphy; Tamara Pagler; Marie Sanson; Sandra Abramowicz; Mani Akhtari; Nora Bijl; Andrea E Bochem; Jan Albert Kuivenhoven; Chao-Ling Kuo; Sonia Tolani; Mi Wang; Carrie Welch; Laurent Yvan-Charvet; Alan R Tall
ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice.
The Journal of clinical investigation 2011;121(10):4138-49.
2011: Hester M den Ruijter; Remco Franssen; Adriaan G Holleboom; Jan Albert Kuivenhoven; Johannes H Levels; Tobias Opthof; Erik S Stroes; Rattapong Sungnoon; Stefan F Vaessen; Diederik F van Wijk; Arie O Verkerk; Ruben Coronel
Reconstituted high-density lipoprotein shortens cardiac repolarization.
Journal of the American College of Cardiology 2011;58(1):40-4.
2011: Georgios Daniil; Alexia A P Phedonos; Adriaan G Holleboom; Mohammad Mahdi Motazacker; Letta Argyri; Jan Albert Kuivenhoven; Angeliki Chroni
Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders.
Clinica chimica acta; international journal of clinical chemistry 2011;412(13-14):1213-20.
2011: M John Chapman; Olivier S Descamps; Edward Fisher; Henry N Ginsberg; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjaerg-Hansen; Gerald F Watts; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
European heart journal 2011;32(11):1345-61.
2011: A G Holleboom; Jan Albert Kuivenhoven; C C van Olden; J Peter; A W Schimmel; Johannes Levels; Robert M Valentijn; P Vos; Joep C Defesche; J J P Kastelein; G Kees Hovingh; E S G Stroes; C E M Hollak
Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase.
Atherosclerosis 2011;216(1):161-5.
2011: Ratna Karuna; Adriaan G Holleboom; Mohammad M Motazacker; Jan Albert Kuivenhoven; Ruth Frikke-Schmidt; Anne Tybjaerg-Hansen; Spiros Georgopoulos; Miranda van Eck; Theo Van berkel; Arnold von Eckardstein; Katharina M Rentsch
Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism.
Atherosclerosis 2011;214(2):448-55.
2011: Menno Vergeer; Suzanne J A Korporaal; Remco Franssen; Illiana Meurs; Ruud Out; G Kees Hovingh; Menno Hoekstra; Jeroen A Sierts; Geesje M Dallinga-Thie; Mohammad Mahdi Motazacker; Adriaan G Holleboom; Theo Van berkel; John J P Kastelein; Miranda van Eck; Jan Albert Kuivenhoven
Genetic variant of the scavenger receptor BI in humans.
The New England journal of medicine 2011;364(2):136-45.
2010: Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjaerg-Hansen
Lipoprotein(a) as a cardiovascular risk factor: current status.
European heart journal 2010;31(23):2844-53.
2010: C Candini; A W Schimmel; J Peter; A E Bochem; A G Holleboom; M Vergeer; R P F Dullaart; Geesje M Dallinga-Thie; G Kees Hovingh; K L Khoo; Tommaso Fasano; Letizia Bocchi; Sebastiano Calandra; Jan Albert Kuivenhoven; Mohammad Mahdi Motazacker
Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol.
Atherosclerosis 2010;213(2):492-8.
2010: Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Journal of lipid research 2010;51(8):2058-73.
2010: Reeni B Hildebrand; Bart Lammers; Illiana Meurs; Suzanne J A Korporaal; Willeke De Haan; Ying Zhao; J Kar Kruijt; Domenico Pratico'; Alinda W M Schimmel; Adriaan G Holleboom; Menno Hoekstra; Jan Albert Kuivenhoven; Theo Van berkel; Patrick C N Rensen; Miranda van Eck
Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(7):1439-45.
2010: Marjan Alssema; Karim El Harchaoui; Roger K Schindhelm; Michaela Diamant; Giel Nijpels; Piet J Kostense; Tom Teerlink; Robert J Heine; Geesje M Dallinga-Thie; Jan Albert Kuivenhoven; Jacqueline M Dekker; Peter G Scheffer
Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study.
Metabolism: clinical and experimental 2010;59(6):854-60.
2010: Mohammad Mahdi Motazacker; John J Kastelein; Jan Albert Kuivenhoven
Are high-density lipoprotein genes and their products targets for therapy?
Current opinion in lipidology 2010;21(2):157-8.
2010: A G Holleboom; Jan Albert Kuivenhoven; M Vergeer; G Kees Hovingh; Joram N I van Miert; Nicholas J Wareham; J J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study.
Journal of lipid research 2010;51(2):416-21.
2009: Karim El Harchaoui; Remco Franssen; G Kees Hovingh; Radjesh J Bisoendial; Frans Stellaard; Folkert Kuipers; John J P Kastelein; Jan Albert Kuivenhoven; Erik S G Stroes; Albert K Groen
Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia.
Atherosclerosis 2009;207(2):614-6.
2009: Stefan F C Vaessen; Robert Jan Veldman; Elisabeth M Comijn; Jolanda Snapper; Jeroen A Sierts; Karin van den Oever; Stuart G Beattie; Jaap Twisk; Jan Albert Kuivenhoven
AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
The journal of gene medicine 2009;11(8):697-707.
2009: Stefan F C Vaessen; Geesje M Dallinga-Thie; Colin J D Ross; L J Splint; L W Castellani; P C N Rensen; Michael R Hayden; Frank G Schaap; Jan Albert Kuivenhoven
Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.
Journal of lipid research 2009;50(5):880-4.
2009: Veronica Hirsch-Reinshagen; James Donkin; Sophie Stukas; Jennifer Chan; Anna Wilkinson; Jianjia Fan; John S Parks; Jan Albert Kuivenhoven; Dieter Lütjohann; Peter Pritchard; Cheryl L Wellington
LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins.
Journal of lipid research 2009;50(5):885-93.
2009: Stefan F C Vaessen; Jeroen A Sierts; Jan Albert Kuivenhoven; Frank G Schaap
Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia.
Biochemical and biophysical research communications 2009;379(2):542-6.
2008: Erik S G Stroes; Melchior C Nierman; Janneke J Meulenberg; Remco Franssen; Jaap Twisk; C Pieter Henny; Mario M Maas; Aeilko H Zwinderman; Colin Ross; Eleonora Aronica; Katherine A High; Marcel M Levi; Michael R Hayden; John J Kastelein; Jan Albert Kuivenhoven
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(12):2303-4.
2008: Dan Ye; A O Kraaijeveld; Robert W Grauss; Stefan Willems; L C van Vark-van der Zee; S C A de Jager; Matti Jauhiainen; Jan Albert Kuivenhoven; Geesje M Dallinga-Thie; Douwe E Atsma; Pancras Hogendoorn; Erik A L Biessen; Theo Van berkel; J Wouter Jukema; Miranda van Eck
Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes.
Journal of internal medicine 2008;264(6):571-85.
2008: Jakub J Regieli; J Wouter Jukema; Diederick Grobbee; John J P Kastelein; Jan Albert Kuivenhoven; Aeilko H Zwinderman; Yolanda van der Graaf; Michiel Bots; Pieter A Doevendans
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
European heart journal 2008;29(22):2792-9.
2008: Bernadette A C van Acker; Gert-Jan Botma; Aeilko H Zwinderman; Jan Albert Kuivenhoven; Geesje M Dallinga-Thie; Eric J G Sijbrands; Jolanda M A Boer; jacob seidell; J Wouter Jukema; John J P Kastelein; Hans Jansen; Adrie J M Verhoeven
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.
Atherosclerosis 2008;200(1):161-7.
2008: Adriaan G Holleboom; Menno Vergeer; G Kees Hovingh; John Jp Kastelein; Jan Albert Kuivenhoven
The value of HDL genetics.
Current opinion in lipidology 2008;19(4):385-94.
2007: Rakesh S Birjmohun; Geesje M Dallinga-Thie; Jan Albert Kuivenhoven; Erik S G Stroes; James D Otvos; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
Circulation 2007;116(18):2029-35.
2007: Melchior C Nierman; Jaap Rip; Jan Albert Kuivenhoven; Naohiko Sakai; John J P Kastelein; Monique G M de Sain-Van Der Velden; Erik S G Stroes; Berthil H C M T Prinsen
Enhanced apoB48 metabolism in lipoprotein lipase X447 homozygotes.
Atherosclerosis 2007;194(2):446-51.
2007: Jaap Rip; Jeroen A Sierts; Stefan F C Vaessen; John J P Kastelein; Jaap Twisk; Jan Albert Kuivenhoven
Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice.
Atherosclerosis 2007;194(1):55-61.
2007: Marijn C Meuwese; Erik S G Stroes; Stanley L Hazen; Joram N I van Miert; Jan Albert Kuivenhoven; Robert G Schaub; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;50(2):159-65.
2007: Rakesh S Birjmohun; Sander I van Leuven; Johannes Levels; Cornelis van 't Veer; Jan Albert Kuivenhoven; Joost C M Meijers; Marcel Levi; John J P Kastelein; Tom van der Poll; Erik S G Stroes
High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(5):1153-8.
2007: John J P Kastelein; Sander I van Leuven; Leslie Burgess; Gregory Evans; Jan Albert Kuivenhoven; Philip J Barter; James H Revkin; Diederick Grobbee; Ward A Riley; Charles L Shear; William T Duggan; Michiel Bots
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
The New England journal of medicine 2007;356(16):1620-30.
2007: Wim A van der Steeg; G Kees Hovingh; Anke H E M Klerkx; Barbara A Hutten; Inge C Nootenboom; Johannes Levels; Arie Van Tol; Geesje M Dallinga-Thie; Aeilko H Zwinderman; John J P Kastelein; Jan Albert Kuivenhoven
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.
Journal of lipid research 2007;48(3):674-82.
2007: Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; Jan Albert Kuivenhoven; James D Otvos; Nicholas J Wareham; Barbara A Hutten; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;49(5):547-53.
2007: Stefan F C Vaessen; Jaap Twisk; John J P Kastelein; Jan Albert Kuivenhoven
Gene therapy in disorders of lipoprotein metabolism.
Current gene therapy 2007;7(1):35-47.
2006: Jaap Rip; Ko Willems van Dijk; Jeroen A Sierts; John J P Kastelein; Jaap Twisk; Jan Albert Kuivenhoven
AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice.
Biochimica et biophysica acta 2006;1761(10):1163-8.
2006: Frank G Schaap; Melchior C Nierman; Jimmy F P Berbée; Hiroaki Hattori; Philippa J Talmud; Stefan F C Vaessen; Patrick Rensen; Robert Chamuleau; Jan Albert Kuivenhoven; Albert K Groen
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.
Journal of lipid research 2006;47(10):2333-9.
2006: Stefan F C Vaessen; Frank G Schaap; Jan Albert Kuivenhoven; Albert K Groen; Barbara A Hutten; S Matthijs Boekholdt; Hiroaki Hattori; Manjinder S Sandhu; Sheila A Bingham; Robert Luben; Jutta A Palmen; Nicholas J Wareham; Steve E Humphries; John J P Kastelein; Philippa J Talmud; Kay-Tee Khaw
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study.
Journal of lipid research 2006;47(9):2064-70.
2006: Jaap Rip; Melchior C Nierman; Colin J D Ross; J Wouter Jukema; Michael R Hayden; John J P Kastelein; Erik S G Stroes; Jan Albert Kuivenhoven
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(6):1236-45.
2006: Colin J D Ross; Jaap Twisk; Andrew C Bakker; Fudan Miao; Dennis Verbart; Jaap Rip; Tamara Godbey; Paul A Dijkhuizen; Wim T Hermens; John J P Kastelein; Jan Albert Kuivenhoven; Janneke M Meulenberg; Michael R Hayden
Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Human gene therapy 2006;17(5):487-99.
2006: Anke H E M Klerkx; Karim El Harchaoui; Wim A van der Steeg; S Matthijs Boekholdt; Erik S G Stroes; John J P Kastelein; Jan Albert Kuivenhoven
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(4):706-15.
2006: S Matthijs Boekholdt; Olga Souverein; Michael W T Tanck; G Kees Hovingh; Jan Albert Kuivenhoven; R I G Peters; H Jansen; Paul M H Schiffers; Ernst E van der Wall; Pieter A Doevendans; P H Reitsma; Aeilko H Zwinderman; J J P Kastelein; J Wouter Jukema
Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels.
Clinical genetics 2006;69(3):263-70.
2006: Jaap Rip; Melchior C Nierman; Nicholas J Wareham; Robert Luben; Sheila A Bingham; Nicholas E Day; Joram N I van Miert; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Kay-Tee Khaw; S Matthijs Boekholdt
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(3):637-42.
2005: Wim A van der Steeg; Karim El Harchaoui; Jan Albert Kuivenhoven; J J P Kastelein
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Current drug targets. Cardiovascular & haematological disorders 2005;5(6):481-8.
2005: Jaap Rip; Melchior C Nierman; Jeroen A Sierts; Wilma Petersen; Karin van den Oever; Daniel Van Raalte; Colin J D Ross; Michael R Hayden; Andrew C Bakker; Paul A Dijkhuizen; Wim T Hermens; Jaap Twisk; Erik S G Stroes; John J P Kastelein; Jan Albert Kuivenhoven; Janneke M Meulenberg
Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Human gene therapy 2005;16(11):1276-86.
2005: Melchior C Nierman; Jaap Rip; Jan Albert Kuivenhoven; Daniel van Raalte; Barbara A Hutten; Naohiko Sakai; John J P Kastelein; Erik S G Stroes
Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance.
Metabolism: clinical and experimental 2005;54(11):1499-503.
2005: Melchior C Nierman; Berthil H C M T Prinsen; Jaap Rip; Robert Jan Veldman; Jan Albert Kuivenhoven; John J P Kastelein; Monique G M de Sain-Van Der Velden; Erik S G Stroes
Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(11):2410-5.
2005: Emily S van Aalst-Cohen; Angelique C M Jansen; S Matthijs Boekholdt; Michael W T Tanck; Marcel R Fontecha; Suzanne Cheng; Jia Li; Joep C Defesche; Jan Albert Kuivenhoven; John J P Kastelein
Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia.
European journal of human genetics : EJHG 2005;13(10):1137-42.
2005: Colin J D Ross; Guoqing Liu; Jan Albert Kuivenhoven; Jaap Twisk; Jaap Rip; Willemijn van Dop; Katherine J D Ashbourne Excoffon; Suzanne M E Lewis; John J Kastelein; Michael R Hayden
Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(10):2143-50.
2005: Pascalle S Monraats; Jamal S Rana; Melchior C Nierman; Nuno M M Pires; Aeilko H Zwinderman; John J P Kastelein; Jan Albert Kuivenhoven; Moniek P M de Maat; Saskia Z H Rittersma; Abbey Schepers; Pieter A Doevendans; Robbert J De Winter; René A Tio; Rune R Frants; Paul H A Quax; Arnoud van der Laarse; Ernst E van der Wall; J Wouter Jukema
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Journal of the American College of Cardiology 2005;46(6):1093-100.
2005: Radjesh J Bisoendial; G Kees Hovingh; Karim El Harchaoui; Johannes Levels; Sotirios Tsimikas; Kewei Pu; Aeilko E Zwinderman; Jan Albert Kuivenhoven; John J P Kastelein; Erik S G Stroes
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):e133-4.
2005: G Kees Hovingh; Barbara A Hutten; Adriaan G Holleboom; Wilma Petersen; Patrick Rol; Anton F H Stalenhoef; Aeilko H Zwinderman; Eric de Groot; John J P Kastelein; Jan Albert Kuivenhoven
Compromised LCAT function is associated with increased atherosclerosis.
Circulation 2005;112(6):879-84.
2005: Jan Albert Kuivenhoven; Greetje J de Grooth; Hitoshi Kawamura; Anke H E M Klerkx; Francois Wilhelm; Mieke D Trip; John J P Kastelein
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
The American journal of cardiology 2005;95(9):1085-8.
2005: G Kees Hovingh; Eric de Groot; Wim A van der Steeg; S Matthijs Boekholdt; Barbara A Hutten; Jan Albert Kuivenhoven; John J P Kastelein
Inherited disorders of HDL metabolism and atherosclerosis.
Current opinion in lipidology 2005;16(2):139-45.
2005: S Matthijs Boekholdt; Frank M Sacks; J Wouter Jukema; James Shepherd; Dilys J Freeman; Alex D McMahon; F Cambien; V Nicaud; Greetje J de Grooth; P J Talmud; S E Humphries; George J Miller; Gudny Eiriksdottir; Vilmundur Gudnason; Heikki Kauma; Sakari Kakko; Markku Savolainen; Marcello Arca; Anna Montali; S Liu; H J Lanz; Aeilko H Zwinderman; Jan Albert Kuivenhoven; J J P Kastelein
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Circulation 2005;111(3):278-87.
2005: Melchior C Nierman; Jaap Rip; Jaap Twisk; J J M Meulenberg; J J P Kastelein; Erik S G Stroes; Jan Albert Kuivenhoven
Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.
The Netherlands journal of medicine 2005;63(1):14-9.
2004: Wim A van der Steeg; Jan Albert Kuivenhoven; Anke H E M Klerkx; S Matthijs Boekholdt; G Kees Hovingh; J J P Kastelein
Role of CETP inhibitors in the treatment of dyslipidemia.
Current opinion in lipidology 2004;15(6):631-6.
2004: Greetje J de Grooth; Anke H E M Klerkx; Erik S G Stroes; Anton F H Stalenhoef; John J P Kastelein; Jan Albert Kuivenhoven
A review of CETP and its relation to atherosclerosis.
Journal of lipid research 2004;45(11):1967-74.
2004: G Kees Hovingh; Alison Brownlie; Radjesh J Bisoendial; Marie Pierre Dube; Johannes Levels; Wilma Petersen; R P F Dullaart; Erik S G Stroes; Aeilko H Zwinderman; Eric de Groot; Michael R Hayden; Jan Albert Kuivenhoven; John J P Kastelein
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease.
Journal of the American College of Cardiology 2004;44(7):1429-35.
2004: S Matthijs Boekholdt; Jan Albert Kuivenhoven; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Robert Luben; Sheila A Bingham; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Circulation 2004;110(11):1418-23.
2004: Colin J D Ross; Jaap Twisk; Janneke M Meulenberg; Guoqing Liu; Karin van den Oever; Ewoud Moraal; Wim T Hermens; Jaap Rip; John J P Kastelein; Jan Albert Kuivenhoven; Michael R Hayden
Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Human gene therapy 2004;15(9):906-19.
2004: S Matthijs Boekholdt; Jan Albert Kuivenhoven; G Kees Hovingh; J Wouter Jukema; John J P Kastelein; Arie Van Tol
CETP gene variation: relation to lipid parameters and cardiovascular risk.
Current opinion in lipidology 2004;15(4):393-8.
2004: Greetje J de Grooth; Tineke J Smilde; Sanne van Wissen; Anke H E M Klerkx; Aeilko H Zwinderman; Jean-Charles Fruchart; John J P Kastelein; Anton F H Stalenhoef; Jan Albert Kuivenhoven
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Atherosclerosis 2004;173(2):261-7.
2004: Greetje J de Grooth; Kim E Zerba; Shu-Pang Huang; Zenta Tsuchihashi; Todd G Kirchgessner; Rene Belder; Priya Vishnupad; Beihong Hu; Anke H E M Klerkx; Aeilko H Zwinderman; J Wouter Jukema; Frank M Sacks; John J P Kastelein; Jan Albert Kuivenhoven
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
Journal of the American College of Cardiology 2004;43(5):854-7.
2004: G Kees Hovingh; Jan Albert Kuivenhoven; Radjesh J Bisoendial; Albert K Groen; Marjel J van Dam; Arie Van Tol; Cheryl L Wellington; Michael R Hayden; August Smelt; J J P Kastelein
HDL deficiency and atherosclerosis: lessons from Tangier disease.
Journal of internal medicine 2004;255(2):299-301.
2004: Anke H E M Klerkx; Greetje J de Grooth; Aeilko H Zwinderman; J Wouter Jukema; Jan Albert Kuivenhoven; J J P Kastelein
Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
European journal of clinical investigation 2004;34(1):21-8.
2003: Jan Albert Kuivenhoven; G Kees Hovingh; Arie Van Tol; M Jauhiainen; C Ehnholm; Jean-Charles Fruchart; E A Brinton; J D Otvos; August Smelt; A Brownlee; Aeilko H Zwinderman; Michael R Hayden; J J P Kastelein
Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size.
Atherosclerosis 2003;171(2):311-9.
2003: Takashi Minami; Jan Albert Kuivenhoven; Valerie Evans; Tatsuhiko Kodama; Robert D Rosenberg; William C Aird
Ets motifs are necessary for endothelial cell-specific expression of a 723-bp Tie-2 promoter/enhancer in Hprt targeted transgenic mice.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(11):2041-7.
2003: Anke H E M Klerkx; Michael W T Tanck; John J P Kastelein; Henri O F Molhuizen; J Wouter Jukema; Aeilko H Zwinderman; Jan Albert Kuivenhoven
Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration.
Human molecular genetics 2003;12(2):111-23.
2002: Greetje J de Grooth; Jan Albert Kuivenhoven; Anton F H Stalenhoef; Jacqueline de Graaf; Aeilko H Zwinderman; Jan L Posma; Arie Van Tol; John J P Kastelein
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Circulation 2002;105(18):2159-65.
2001: JM Boer; Edith J M Feskens; Jan Albert Kuivenhoven; EG Schouten; LM Havekes; John J P Kastelein; jacob seidell; Daan Kromhout
Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle.
Atherosclerosis 2001;155(1):149-56.
2000: V Evans; AK Hatzopoulos; William C Aird; Helen Rayburn; R D Rosenberg; Jan Albert Kuivenhoven
Targeting the Hprt locus in mice reveals differential regulation of Tie2 gene expression in the endothelium.
Physiological genomics 2000;2(2):67-75.
1999: JM Boer; Jan Albert Kuivenhoven; Edith J M Feskens; EG Schouten; LM Havekes; jacob seidell; John J P Kastelein; Daan Kromhout
Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins.
Clinical genetics 1999;56(2):158-63.
1998: M Li; Jan Albert Kuivenhoven; Amir F Ayyobi; P Haydn Pritchard
T-->G or T-->A mutation introduced in the branchpoint consensus sequence of intron 4 of lecithin:cholesterol acyltransferase (LCAT) gene: intron retention causing LCAT deficiency.
Biochimica et biophysica acta 1998;1391(2):256-64.
1998: Jan Albert Kuivenhoven; J Wouter Jukema; Aeilko H Zwinderman; P de Knijff; R McPherson; A V G Bruschke; KI Lie; John J P Kastelein
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
The New England journal of medicine 1998;338(2):86-93.
1997: B E Groenemeijer; M D Hallman; PW Reymer; E Gagné; Jan Albert Kuivenhoven; T Bruin; Hans Jansen; KI Lie; A V G Bruschke; E Boerwinkle; Michael R Hayden; John J P Kastelein
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Circulation 1997;95(12):2628-35.
1997: Jan Albert Kuivenhoven; BE Groenemeyer; JM Boer; PW Reymer; R Berghuis; T Bruin; Hans Jansen; jacob seidell; John J P Kastelein
Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):595-9.
1997: Jan Albert Kuivenhoven; P de Knijff; JM Boer; H A Smalheer; G J Botma; jacob seidell; John J P Kastelein; P Haydn Pritchard
Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):560-8.
1997: Jan Albert Kuivenhoven; Peter Pritchard; J Hill; J Frohlich; G Assmann; John J P Kastelein
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
Journal of lipid research 1997;38(2):191-205.
1996: Jan Albert Kuivenhoven; H Weibusch; P Haydn Pritchard; Harald Funke; Rob Benne; G Assmann; John J P Kastelein
An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).
The Journal of clinical investigation 1996;98(2):358-64.
1996: Jan Albert Kuivenhoven; A F Stalenhoef; J S Hill; P N Demacker; a Errami; John J P Kastelein; P Haydn Pritchard
Two novel molecular defects in the LCAT gene are associated with fish eye disease.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(2):294-303.
1995: Jan Albert Kuivenhoven; E J van Voorst tot Voorst; H Wiebusch; S M Marcovina; Harald Funke; G Assmann; P Haydn Pritchard; John J P Kastelein
A unique genetic and biochemical presentation of fish-eye disease.
The Journal of clinical investigation 1995;96(6):2783-91.
1992: John J P Kastelein; P Haydn Pritchard; D W Erkelens; Jan Albert Kuivenhoven; J J Albers; J J Frohlich
Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent.
Journal of internal medicine 1992;231(4):413-9.